Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Deep clinical evidence library with data collected from more than 1,400 subjects demonstrating dramatic improvement over today's standard of care
IONIQ's ProLung Test designated “Breakthrough Device” by US FDA for its life-enhancing potential
More than 25 premier cancer institutions across 3 continents have participated in our clinical trials
Collaborating with medical and scientific experts
Robust, growing intellectual portfolio of 22 issued and filed patents plus expert know-how
Salt Lake City, UT, May 30, 2023 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that Mr. Jared Bauer, CEO, will present in-person at the 13th annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on June
Salt Lake City, UT, May 19, 2023 – We’re pleased to announce that Jared Bauer, IONIQ Sciences CEO, was interviewed on the Empowered Patient Podcast in their recent episode, “Using Bioimpedance-Based Technology for Early Detection of Cancer.” Mr. Bauer highlights the core technology of IONIQ’s
Salt Lake City, UT, April 14, 2023 – IONIQ Sciences is pleased to announce that Richard Ferguson, MD is our Clinical Trial Ambassador. Dr. Ferguson is helping ensure that IONIQ’s clinical trial enrollment is appropriately diverse (race, ethnicity, gender and backgrounds). Dr. Ferguson is currently
